Condor.

Here is a fact about the pharmaceutical industry that would sound made up if it weren't so thoroughly documented: some of the most sophisticated science on the planet - molecules designed atom by atom to interrupt a disease pathway - is financially managed in Microsoft Excel. Not the trial design. Not the chemistry. The money. The billions of dollars that flow to contract research organizations, to trial sites, to labs and imaging vendors and data managers, all tracked in spreadsheets that a finance analyst emails around and prays nobody has broken a formula in.

Condor Software, a San Diego company founded in 2020, exists because of that gap. Its pitch is narrow and, once you sit with it, faintly outrageous: clinical trial finance is one of drug development's last great spreadsheet workflows, and it is enormous, and it is a mess, and someone should build real software for it. Condor is that someone. It calls the result a "Financial Intelligence Platform," which is the kind of phrase that usually means nothing, except in this case it means something quite specific - a system that ingests clinical, operational, and financial data from all the places it lives and reconciles it into one number a chief financial officer can actually trust.

The reason this is hard is worth explaining, because the difficulty is the whole business. A clinical trial is a promise to spend money over several years on activities that haven't happened yet, run by outside vendors who bill on their own schedules, for work whose pace you don't fully control. Accountants have to book the cost of that work as it is performed - "accruals," in the trade - which means estimating, every month, how much of a multi-year, multi-vendor, multi-site study has actually been consumed. Get it wrong and you either flatter your burn rate or panic your board. The data you'd need to get it right sits in a clinical trial management system, an electronic data capture system, an ERP, and a pile of vendor invoices, none of which talk to each other. So people export it all to Excel and do their best.

That line, from founder and CEO Jennifer Kyle, is the emotional core of the company and also a genuinely interesting claim about how drugs die. We tend to imagine a failed therapy as a scientific failure - the molecule didn't work, the trial missed its endpoint. Kyle, a CPA who came up through the finance side of life sciences, is pointing at a quieter failure mode: a program that gets cut not because the science is bad but because the numbers in the room were stale, and the stale numbers made the program look more expensive or riskier than it actually was. If you believe that even occasionally happens, then better financial data isn't a back-office nicety. It's upstream of which medicines get made.

What the thing actually does

Condor's platform is organized around three pieces with the tidy alliteration that product teams cannot resist. Connect is the plumbing: it pulls in data from CTMS, EDC, ERP, and vendor systems - the Veevas and Medidatas and NetSuites of the world - and reconciles it so that the clinical version of reality and the financial version of reality finally agree. Copilot is the AI layer that automates the grunt work: accruals, journal entries, the monthly close that finance teams describe with the same enthusiasm most people reserve for jury duty. Compass is where the finished numbers become decisions - forecasting, budgeting, scenario planning, portfolio benchmarking, the board-ready charts.

The claims Condor makes for this are specific enough to be checkable, which is itself a good sign. Customers, it says, reach north of 90% forecast accuracy and close their books up to 70% faster than they did on spreadsheets. A director of R&D accounting at Alumis, one of Condor's customers, put it in the blunt language of someone who has actually done a month-end close: "Automating all previously manual work is life changing. We expect a thirty to forty percent efficiency boost." That is not the sentence of a person being polite about a demo.

The money, and who believes in it

In March 2026, Condor raised a $24 million Series A led by Insight Partners, the large software investor, with a supporting cast - Felicis, 645 Ventures, Pamir Ventures, SNR Ventures, Prebys Ventures, and Bramalea Partners - that reads like a who's-who of firms comfortable underwriting unglamorous, vertical, mission-critical software. The round brought Condor's total funding to roughly $36 million. Insight's VP Alexander Leibowitz framed the bet in category terms: "Jennifer is creating a new category in financial products for pharmaceutical companies." Investors love the word "category" because a category is a moat you build rather than one you find, and vertical finance software - finance tools built for exactly one industry and nobody else - has been quietly minting durable businesses for a decade.

The proof point Condor likes to cite is the amount of money already flowing across the platform: on the order of $19 billion in R&D spend. That is a striking number for a company of roughly 120 people, and it is the kind of figure that makes an investor's arithmetic work. You don't need to capture a large fraction of $19 billion in fees to build something valuable; you need to be the system of record that the $19 billion cannot easily leave.

Who's actually using it

Condor's customer list is its resume: Acadia, Alumis, BridgeBio, Madrigal - biotechs that are, notably, real drug companies with real programs and real boards asking real questions about burn. These are not logos of convenience. When your customers are trying to move therapies through the clinic, your software stops being a productivity toy and starts being part of how they decide what to fund. That raises the stakes on the boring stuff Condor takes seriously - audit trails, SOX and SOC controls, the compliance scaffolding that regulated finance teams need before they'll let a new system near the general ledger.

It is tempting, writing about a company like this, to reach for the language of transformation. Condor's own materials mostly resist it, and the more persuasive story is smaller and more concrete: a specific, expensive, universally-loathed workflow - reconciling what a clinical trial cost against what its vendors billed - being handed to software that was designed for exactly that job. The competition, tellingly, is not really other startups. It's the spreadsheet, and the homegrown internal tool that some overworked analyst built and now cannot leave the company for fear it breaks. Beating incumbents is hard. Beating Excel is a different kind of hard: Excel is free, familiar, and already installed. You beat it by being so obviously better at one painful thing that switching feels like relief.

That is Condor's wager. Not that biotech finance teams want new software - nobody wants new software - but that they want their month-end close back, their forecast to hold, and their next budget meeting to run on numbers that were true this morning rather than last quarter. If Kyle is right that programs sometimes die on stale data, then the most valuable thing Condor sells isn't automation at all. It's the absence of a bad surprise.